Tilmann Bochtler

7PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 03, 2026
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

|Apr 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.

|Dec 08, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Anne Sophie Platzbecker, Julia-Annabell Georgi, Jan Moritz Middeke

|Aug 04, 2025
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.

Maria Pouyiourou, Tilmann Bochtler, Chantal Pauli

|Jan 04, 2024
Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary.

Maria Pouyiourou, Tilmann Bochtler, Cornelia Coith

|Apr 17, 2022
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary.

Tilmann Bochtler, Timothy Wohlfromm, Thomas Hielscher

Pageof 2

Frequent Collaborators

5 joint publications

Albrecht Stenzinger

4 joint publications

Alwin Krämer

2 joint publications

Maria Pouyiourou

2 joint publications

Klaus Pantel